Αρχική Basic and Clinical Research

Basic and Clinical Research

Our research focuses on the following topics:

 

1. Atherosclerosis – Thrombosis – Vascular Biology

2. Heart Failure

3. Pulmonary Embolism

4. Arterial Hypertension

5. Atrial Fibrillation

6. Pharmacogenetics

 

 

1. Atherosclerosis – Thrombosis – Vascular Biology

 

1.1. Mechanisms of destabilisation and rupture of atherosclerotic plaques

 

►    Publications 

Alteplase treatment affects circulating matrix metalloproteinase concentrations in patients with ST segment elevation acute myocardial infarction.

Tziakas DN, Chalikias GK, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris A, Hatseras DI, Kaski JC. Thromb Res 2006;118:221-7.

Gelatinases [matrix metalloproteinase-2 (MMP-2) and MMP-9] induce carotid plaque instability but their systemic levels are not predictive of local events.

Tziakas DN, Lazarides MK, Tentes IK, Georgiadis GS, Eleftheriadou E, Chalikias GK, Kortsaris A, Hatseras DI. Ann Vasc Surg 2005;19:529-33.

Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration.

Tziakas DN, Chalikias GK, Parissis JT, Hatzinikolaou EI, Papadopoulos ED, Tripsiannis GA, Papadopoulou EG, Tentes IK, Karas SM, Chatseras DI. Int J Cardiol 2004;94:269-77.

Anti-inflammatory cytokine profile in acute coronary syndromes: behavior of interleukin-10 in association with serum metalloproteinases and proinflammatory cytokines.

Tziakas DN, Chalikias GK, Hatzinikolaou HI, Parissis JT, Papadopoulos ED, Trypsianis GA, Papadopoulou E, Tentes IK, Karas SM, Hatseras DI. Int J Cardiol 2003;92:169-75.

Leukocyte activation after coronary stenting in patients during the subacute phase of a previous ST-elevation myocardial infarction.

Stakos DA, Kotsianidis I, Tziakas DN, Spanoudakis E, Chalikias G, Bourikas G, Katsaris G, Boudoulas H. Coron Artery Dis 2007;18:105-10.

►    Prizes and Awards 

23rd Panhellenic Cardiology Congress, Athens 2002. “Interleukin-10 levels in acute coronary syndromes: association with serum metalloproteinases”

2nd Annual Congress on Atherosclerosis, Thessaloniki 2008. “Inflammatory and immune response to angioplasty following acute myocardial infarction”

4th Annual Congress on Atherosclerosis, Thessaloniki 2008. “From hyperlipidaemia to atherosclerosis: the role of ΝΚΤ lymphocytes and the effects of statins”

 


 

1.2. Clarification of the role of erythrocytes in the pathophysiology of atherosclerosis, focusing on their total and free cholesterol load, and on membrane chemokines.

►    Publications 

Independent and additive predictive value of total cholesterol content of erythrocyte membranes with regard to coronary artery disease clinical presentation.

Tziakas DN, Chalikias GK, Stakos D, Tentes IK, Papazoglou D, Thomaidi A, Grapsa A, Gioka G, Kaski JC, Boudoulas H. Int J Cardiol 2010 Mar 9. [Epub ahead of print]

The role of red blood cells in the progression and instability of atherosclerotic plaque.

Tziakas DN, Chalikias GK, Stakos D, Boudoulas H. Int J Cardiol 2010;142:2-7.

Statin use is associated with a significant reduction in cholesterol content of erythrocyte membranes. A novel pleiotropic effect?

Tziakas DN, Chalikias GK, Stakos D, Tentes IK, Thomaidi A, Chatzikyriakou S, Mitrousi K, Kortsaris AX, Kaski JC, Boudoulas H, Konstantinides S. Cardiovasc Drugs Ther 2009;23:471-80.

Cholesterol composition of erythrocyte membranes and its association with clinical presentation of coronary artery disease.

Tziakas DN, Chalikias GK, Stakos D, Tentes IK, Chatzikyriakou SV, Mitrousi K, Kortsaris AX, Boudoulas H, Kaski JC. Coron Artery Dis 2008;19:583-90.

Interleukin-8 is increased in the membrane of circulating erythrocytes in patients with acute coronary syndrome.

Tziakas DN, Chalikias GK, Tentes IK, Stakos D, Chatzikyriakou SV, Mitrousi K, Kortsaris AX, Kaski JC, Boudoulas H. Eur Heart J 2008;29:2713-22.

Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability?

Tziakas DN, Kaski JC, Chalikias GK, Romero C, Fredericks S, Tentes IK, Kortsaris AX, Hatseras DI, Holt DW. J Am Coll Cardiol 2007;49:2081-9.

 

►    Prizes and Awards  

Young Investigator Award in Clinical Science, Congress of the European Society of Cardiology, Stockholm 2005. “Erythrocyte membrane cholesterol content contributing to clinical instability in acute coronary syndromes?”

Υοung Investigator Αward in Coronary Pathophysiology and Microcirculation, Congress of the European Society of Cardiology, Barcelona 2009. “Independent and additive predictive value of total cholesterol content of erythrocyte membranes with regard to coronary artery disease clinical presentation”.

26th Panhellenic Cardiology Congress, Athens 2005. “Total cholesterol content of erythrocyte membranes is not associated with circulating lipid levels in patients with acute coronary syndrome”.

27th Panhellenic Cardiology Congress, Athens 2006. “Total and free cholesterol content of erythrocyte membranes as prognostic markers in patients with coronary artery disease.”

2nd Panhellenic Congress on Atherosclerosis, Athens 2006. “Increased content of free cholesterol of erythrocyte membranes is associated with clinical instability in patients with coronary artery disease”.

29th Panhellenic Cardiology Congress, Athens 2008. “Increased levels of interleukin -8 in erythrocyte membranes are associated with acute coronary syndromes”.

First Cardiovascular Research Award, 3rd Panhellenic Congress on Atherosclerosis, Athens 2008. “Use of statins is associated with a significant reduction in cholesterol content of erythrocyte membranes. A novel pleiotropic action of statins?”

First Cardiovascular Research Award, 4th Panhellenic Congress on Atherosclerosis, Ioannina 2010. “Cholesterol content of erythrocyte membranes is associated with atherosclerotic lipid core size in animal models of atherosclerosis.”

 

►    Research protocol funding 

29th Panhellenic Cardiology Congress, Athens 2008. “Fluctuations of cholesterol content of erythrocyte membranes and associated changes in morphologic characteristics of atherosclerotic plaque. Effect of statins on atherosclerotic plaque progression and regression.” (12,000 Euros)

30th Panhellenic Cardiology Congress, Athens 2009. «Impact of sphingomylein concentrations on cholesterol loading of erythrocyte membranes  and on extent and vulnerability of atherosclerotic plaques in animal models of atherosclerosis. Effect of statins and myriocin atherosclerotic plaque progression and regression.”  (5,000 Euros)

 


 

 

1.3. Acute renal failure following myocardial infarction – identification of diagnostic and prognostic markers

Ongoing studies: Development of a prognostic model for contrast-induced nephropathy (CIN) following percutaneous coronary interventions.

 


 

 

1.4. New biomarkers in the diagnosis and prognosis of coronary artery disease

We have developed and continue to optimise prognostic models taking into account the (im)balance between pro- and anti-inflammatory mediators.

►    Publications 

Interleukin-18/interleukin-10 ratio is an independent predictor of recurrent coronary events during a 1-year follow-up in patients with acute coronary syndrome.

Chalikias GK, Tziakas DN, Kaski JC, Kekes A, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris AX, Hatseras DI. Int J Cardiol 2007;117:333-9.

Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: a factor analysis approach.

Tziakas DN, Chalikias GK, Kaski JC, Kekes A, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris AX, Hatseras DI. Atherosclerosis 2007;193:196-203.

Interleukin-18: interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome.

Chalikias GK, Tziakas DN, Kaski JC, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris A, Hatseras DI. Atherosclerosis 2005;182:135-43.

 

►    Awards 

Young Investigator Award in Coronary Pathophysiology and Microcirculation, in World Congress of Cardiology, Barcelona 2006. “Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients. A factor analysis approach”.

 




2. Heart Failure

We are investigating the contribution of extracellular matrix turnover to cardiac remodeling and the pathophysiology of heart failure. Our focus is on matrix metalloproteinases and on collagen type I synthesis and degradation products.

 

►    Publications 

Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: a multi-marker approach with high-negative predictive value to rule out long-term adverse events.

Tziakas DN, Chalikias GK, Stakos D, Chatzikyriakou SV, Papazoglou D, Mitrousi K, Lantzouraki A, Thomaidi A, Boudoulas H, Konstantinides S. Eur J Cardiovasc Prev Rehabil. 2010 May 14. [Epub ahead of print]

Chronic heart failure patients with high collagen type I degradation marker levels benefit more with ACE-inhibitor therapy.

Chatzikyriakou SV, Tziakas DN, Chalikias GK, Stakos D, Thomaidi A, Mitrousi K, Boudoulas H. Eur J Pharmacol. 2010;628(1-3):164-70

Cardiovascular involvement in patients with beta-thalassemia major without cardiac iron overload.

Stakos DA, Margaritis D, Tziakas DN, Kotsianidis I, Chalikias GK, Tsatalas K, Bourikas G, Boudoulas H. Int J Cardiol. 2009;134(2):207-11.

Resolution of symptoms and serum peptides of collagen type I turnover in acute heart failure patients.

Chatzikyriakou SV, Tziakas DN, Chalikias GK, Stakos DA, Thomaidi AK, Mitrousi K, Lantzouraki AE, Kotsiou S, Maltezos E, Boudoulas H. Acta Cardiol. 2009;64(1):29-33.

Levosimendan use reduces matrix metalloproteinase-2 in patients with decompensated heart failure.

Tziakas DN, Chalikias GK, Hatzinikolaou HI, Stakos DA, Papanas N, Tentes IK, Kortsaris AX, Maltezos E, Hatseras DI, Kaski JC. Cardiovasc Drugs Ther. 2005;19(6):399-402.

Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy.

Tziakas DN, Chalikias GK, Papaioakeim M, Hatzinikolaou EI, Stakos DA, Tentes IK, Papanas N, Kortsaris A, Maltezos E, Hatseras DI. Am J Cardiol. 2005;96(10):1449-51.

N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction.

Tziakas DN, Chalikias GK, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris A, Hatseras DI, Kaski JC. Am J Cardiol. 2005;96(1):31-4

Prolonged activation of tumor necrosis factor (TNF)-alpha and its soluble receptors in chronic heart failure patients both in the compensated and decompensated state. Interplay between their levels and metalloproteinase-3.

Tziakas D, Chalikias G, Parissis JT, Hatzinikolaou H, Stakos D, Papadopoulou E, Kortsaris A, Hatseras D. Eur Cytokine Netw. 2004;15(3):231-9.

 

►    Prizes and Awards 

4th Panhellenic Annual Congress on Heart Failure. “Serum levels of metalloproteinases and their inhibitors in patients with acute decompensation of chronic heart failure”

6th Panhellenic Annual Congress on Heart Failure. “Levels of MMP 2 and 9 are increased in patients with cardiac cachexia”

Back to the top



 

 

3. Pulmonary Embolism

In collaboration with the University of Goettingen, Germany, and a network of centres of excellence in Pulmonary Embolism (PE), we focus on the risk stratification of acute PE based on clinical scores, imaging modalities, and biochemical markers of right ventricular dysfunction and myocardial necrosis. Our aims are (i) to optimise the definition and diagnosis of intermediate-risk PE, and identify possible candidates for early thrombolysis amongst normotensive patients, and (ii) to establish criteria for safely treating patients with low-risk PE on an outpatient basis.

 

Pulmonary Embolism Thrombolysis Study (PEITHO)

A prospective, randomised, double-blind, placebo-controlled, international, multicentre, parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus tenecteplase plus standard anticoagulation as compared with standard anticoagulation in normotensive patients with acute pulmonary embolism and with echocardiographic (or spiral CT) and laboratory evidence of right ventricular dysfunction.

Sponsor: Assistance Publique d’ Hôpitaux de Paris

ClinicalTrials.gov Identifier: NCT00639743

Status: Recruiting

Chairman of the international steering committee): Prof. S. Konstantinides

 

►    Publications 

Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism.

Puls M, Dellas C, Lankeit M, Olschewski M, Binder L, Geibel A, Reiner C, Schäfer K, Hasenfuss G, Konstantinides S. Eur Heart J 2007;28:224-229.

Heart-type fatty acid-binding protein for risk stratification of patients with chronic thromboembolic pulmonary hypertension.

Lankeit M, Dellas C, Panzenböck A, Skoro-Sajer N, Bonderman D, Olschewski M, Schäfer K, Puls M, Konstantinides S, Lang IM. Eur Resp J 2008;31:1024-1029.

Growth-differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism.

Lankeit M, Kempf T, Dellas C, Cuny M, Olschewski M, Tapken H, Peter T, Konstantinides S, Wollert KC. Am J Resp Crit Care 2008;177:1018-1025.

Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC).

Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszcsyk P et al. Eur Heart J 2008;29:2276-2315.

Desmoteplase in acute massive pulmonary thromboembolism.

Tebbe U, Bramlage P, Graf A, Lechleitner P, Bode C, Riess FC, Clemens N, Al-Rawi Y, Konstantinides S, Goldhaber SZ. Thromb Haemost 2009;101:557-562.

Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism.

Dellas C, Puls M, Lankeit M, Schäfer K, Cuny M, Berner M, Hasenfuss G, Konstantinides S. J Am Coll Cardiol 2010;55:2150-2157.

Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism.

Lankeit M, Friesen D, Aschoff J, Dellas C, Hasenfuß G, Katus H, Konstantinides S, Giannitsis E. Eur Heart J 2010;31:1836-1844.

Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism.

Jiménez D, Aujesky D, Moores L, Gómez V, Martí D, Briongos S, Monreal M, Barrios V, Konstantinides S, Yusen RD. Thorax 2010 [Epub ahead of print].

 

Back to the top



 

 

4. Arterial Hypertension

We are investigating the influence of extracellular matrix turnover within the intima and media on the elastic properties of the arterial tree. Our focus is on matrix metalloproteinases and on collagen type I synthesis and degradation products.

Ongoing studies: Pathophysiological mechanisms and prediction models for hypertensive crisis

 

►    Publications 

Associations between collagen synthesis and degradation and aortic function in arterial hypertension.

Stakos DA, Tziakas DN, Chalikias GK, Mitrousi K, Tsigalou C, Boudoulas H. Am J Hypertens 2010;23:488-94.

Oxidised low-density lipoprotein and arterial function in beta-thalassemia major.

Stakos DA, Tavridou A, Margaritis D, Tziakas DN, Kotsianidis I, Chalikias GK, Tsatalas K, Bourikas G, Manolopoulos VG, Boudoulas H. Eur J Haematol 2009;82:477-83.

Serum levels of collagen type-I degradation markers are associated with vascular stiffness in chronic heart failure patients.

Chatzikyriakou SV, Tziakas DN, Chalikias GK, Stakos DA, Thomaidi AK, Mitrousi K, Lantzouraki AE, Kotsiou S, Maltezos E, Boudoulas H. Eur J Heart Fail 2008;10:1181-5.

►    Awards 

Research protocol funding, 31st Panhellenic Cardiology Congress, Athens 2010. “Correlation between the serum/urine sodium ratio and plasma rennin in patients with hypertensive crisis: a potential aid in choosing the appropriate antihypertensive therapy”

Back to the top



 

5. Atrial Fibrillation

We are investigating the involvement of extracellular matrix turnover in the appearance and perpetuation of atrial fibrillation, and the response to antiarrhythmic treatment. Our focus is on matrix metalloproteinases and on collagen type I synthesis and degradation products.

 

►    Publications 

Effect of statins on collagen type I degradation in patients with coronary artery disease and atrial fibrillation.

Tziakas DN, Chalikias GK, Stakos DA, Papanas N, Chatzikyriakou SV, Mitrousi K, Maltezos E, Boudoulas H. Am J Cardiol 2008;101:199-202.

Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation.

Tziakas DN, Chalikias GK, Papanas N, Stakos DA, Chatzikyriakou SV, Maltezos E. Europace 2007;9:589-96.

 

Back to the top




 

6. Genetics and Pharmnacogenetics

 

►    Publications 

Role of apolipoprotein E genotype in coronary artery disease.

Tziakas DN, Chalikias GK. Future Cardiol 2007;3:537-51.

Apolipoprotein E genotype and circulating interleukin-10 levels in patients with stable and unstable coronary artery disease.

Tziakas DN, Chalikias GK, Antonoglou CO, Veletza S, Tentes IK, Kortsaris AX, Hatseras DI, Kaski JC. J Am Coll Cardiol 2006;48:2471-81.

Effect of angiotensin-converting enzyme insertion/deletion genotype on collagen type I synthesis and degradation in patients with atrial fibrillation and arterial hypertension.

Tziakas DN, Chalikias GK, Stakos DA, Papazoglou D, Papanas N, Papatheodorou K, Chatzikyriakou SV, Kotsiou S, Maltezos E, Boudoulas H. Expert Opin Pharmacother 2007;8:2225-34.

 

Back to the top


 

 

Access and Contact Details

Click on the map to see our location.
Department Secretariat
Phone: +30 25510 76231
Fax: +30 25510 76245
email: cardio@med.duth.gr

Κατασκευή Ιστοσελίδας Πανεπιστημιακή Καρδιολογική Κλινική 2010 | Επικοινωνία | Αρχική